Chun-Yi Hao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2985497/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Contralateral internal iliac artery transposition for retroperitoneal sarcoma involving common iliac artery. Updates in Surgery, 2022, 74, 1157-1163.	2.0	2
2	Hepatic Artery Injection of ¹³¹ I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial. Journal of Nuclear Medicine, 2022, 63, 556-559.	5.0	9
3	Long non‑coding RNA LINC00238 suppresses the malignant phenotype of liver cancer by sponging miR‑522. Molecular Medicine Reports, 2022, 25, .	2.4	3
4	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. Radiology, 2022, 303, 455-464.	7.3	53
5	Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study Journal of Clinical Oncology, 2022, 40, 383-383.	1.6	84
6	Development and validation of a nomogram for predicting the prognosis in cancer patients with sepsis. Cancer Medicine, 2022, , .	2.8	2
7	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surgery and Nutrition, 2022, 11, 227-252.	1.5	55
8	A novel nomogram for predicting local recurrence-free survival after surgical resection for retroperitoneal liposarcoma from a Chinese tertiary cancer center. International Journal of Clinical Oncology, 2021, 26, 145-153.	2.2	16
9	Prediction of Histologic Subtype and FNCLCC Grade by SUVmax Measured on 18F-FDG PET/CT in Patients with Retroperitoneal Liposarcoma. Contrast Media and Molecular Imaging, 2021, 2021, 1-8.	0.8	10
10	Correlation between early brain natriuretic peptide level and mortality in cancer patients with septic shock. Annals of Palliative Medicine, 2021, 10, 4214-4219.	1.2	0
11	Expression of Death Associated Proteins DAP1 and DAP3 in Human Pancreatic Cancer. Anticancer Research, 2021, 41, 2357-2362.	1.1	4
12	Brain natriuretic peptide and cardiac troponin I for prediction of the prognosis in cancer patients with sepsis. BMC Anesthesiology, 2021, 21, 159.	1.8	2
13	Reduced kinase D‑interacting substrate of 220ÂkDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression. International Journal of Oncology, 2021, 58, .	3.3	2
14	A phase I study to evaluate the safety and effectiveness of neoantigen-based personalized dendritic cell vaccine in patients with advanced solid tumors Journal of Clinical Oncology, 2021, 39, e14512-e14512.	1.6	0
15	A retrospective study to evaluate the safety and efficacy of anlotinib plus camrelizumab in management of advanced retroperitoneal sarcoma Journal of Clinical Oncology, 2021, 39, e23545-e23545.	1.6	1
16	Predictive Value of Preoperative Controlling Nutritional Status Score Combined with Fibrinogen–Albumin Ratio in Postoperative Local Recurrence-Free Survival of Patients with Retroperitoneal Liposarcoma. Cancer Management and Research, 2021, Volume 13, 6157-6167.	1.9	5
17	The role of coeliac axis resection in resected ductal adenocarcinoma of the distal pancreas: A result of tumour topography or a prognostic factor?. Pancreatology, 2021, 22, 112-112.	1.1	1
18	OTU-17â€Expression, clinical and prognostic value of dual specific protein phosphatase-7 (DUSP-7) in pancreatic cancer. , 2021, , .		0

CHUN-YI HAO

#	Article	IF	CITATIONS
19	PTU-68â€The Expression and Clinical Significance of MLN64 in Human Pancreatic Cancer. , 2021, , .		0
20	Macroscopically complete excision is a beneficial strategy for selected patients with peritoneal sarcomatosis. BioScience Trends, 2021, , .	3.4	1
21	Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma. Frontiers in Oncology, 2021, 11, 739139.	2.8	5
22	Establishment of a multi-parameters MRI model for predicting small lymph nodes metastases (<10Âmm) in patients with resected pancreatic ductal adenocarcinoma. Abdominal Radiology, 2021, , 1.	2.1	2
23	Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. Journal of Pharmaceutical and Biomedical Analysis, 2020, 179, 112980.	2.8	11
24	Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses. Journal of Pharmaceutical Sciences, 2020, 109, 1169-1177.	3.3	5
25	Pancreaticoduodenectomy for Retroperitoneal Sarcomas: A Mono-Institutional Experience in China. Frontiers in Oncology, 2020, 10, 548789.	2.8	4
26	Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma. Life Sciences, 2020, 260, 118302.	4.3	7
27	Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer. International Journal of Medical Sciences, 2020, 17, 3073-3081.	2.5	13
28	<p>Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance</p> . OncoTargets and Therapy, 2020, Volume 13, 6523-6537.	2.0	10
29	<p>CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors</p> . OncoTargets and Therapy, 2020, Volume 13, 12615-12623.	2.0	6
30	Dexamethasone inhibits pancreatic tumor growth in preclinical models: Involvement of activating glucocorticoid receptor. Toxicology and Applied Pharmacology, 2020, 401, 115118.	2.8	18
31	Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 618215.	2.8	15
32	Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence. Oncology Reports, 2020, 44, 565-576.	2.6	7
33	Cytoreductive surgery for metastatic gastrointestinal stromal tumorsÂfollowed by sunitinib compared to followed by imatinib-aÂmulti-center cohort study. European Journal of Surgical Oncology, 2019, 45, 318-323.	1.0	6
34	>Downregulation of TfR1 promotes progression of colorectal cancer via the JAK/STAT pathway. Cancer Management and Research, 2019, Volume 11, 6323-6341.	1.9	35
35	N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation. Toxicology and Applied Pharmacology, 2019, 384, 114789.	2.8	8
36	Wnt-11 Expression Promotes Invasiveness and Correlates with Survival in Human Pancreatic Ductal Adeno Carcinoma. Genes, 2019, 10, 921.	2.4	10

Сним-Үі Нао

#	Article	IF	CITATIONS
37	Comprehensive immune characterization and Tâ€cell receptor repertoire heterogeneity of retroperitoneal liposarcoma. Cancer Science, 2019, 110, 3038-3048.	3.9	31
38	GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy. Theranostics, 2019, 9, 2167-2182.	10.0	80
39	Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects. Frontiers of Medicine, 2019, 13, 427-437.	3.4	16
40	Biomineralization Synthesis of the Cobalt Nanozyme in SP94-Ferritin Nanocages for Prognostic Diagnosis of Hepatocellular Carcinoma. ACS Applied Materials & Interfaces, 2019, 11, 9747-9755.	8.0	77
41	T cell receptor βâ€chain repertoire analysis of tumorâ€infiltrating lymphocytes in pancreatic cancer. Cancer Science, 2019, 110, 61-71.	3.9	16
42	Establishment of pancreatic cancer patient-derived xenograft models and comparison of the differences among the generations. American Journal of Translational Research (discontinued), 2019, 11, 3128-3139.	0.0	7
43	Clinicopathological features and prognostic factors of solid pseudopapillary neoplasms of pancreas. Pakistan Journal of Pharmaceutical Sciences, 2019, 32, 459-464.	0.2	5
44	Is Central Pancreatectomy Truly Recommendable? A 9-Year Single-Center Experience. Digestive Surgery, 2018, 35, 532-538.	1.2	15
45	Time-dependent pharmacokinetics of dexamethasone and its efficacy in human breast cancer xenograft mice: a semi-mechanism-based pharmacokinetic/pharmacodynamic model. Acta Pharmacologica Sinica, 2018, 39, 472-481.	6.1	20
46	<i>En bloc</i> resection for intra-abdominal/retroperitoneal desmoid-type fibromatosis with adjacent organ involvement: A case series and literature review. BioScience Trends, 2018, 12, 620-626.	3.4	7
47	Infiltration characteristics and influencing factors of retroperitoneal liposarcoma: Novel evidence for extended surgery and a tumor grading system. BioScience Trends, 2018, 12, 185-192.	3.4	17
48	Precise Navigation of the Surgical Plane with Intraoperative Real-time Virtual Sonography and 3D Simulation in Liver Resection. Journal of Gastrointestinal Surgery, 2018, 22, 1814-1818.	1.7	11
49	Use of 18F-FDG-PET/CT for Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas. Contrast Media and Molecular Imaging, 2018, 2018, 1-8.	0.8	13
50	Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. BMC Cancer, 2018, 18, 247.	2.6	10
51	Anterior Approach to En Bloc Resection in Left-Sided Retroperitoneal Sarcoma with Adjacent Organ Involvement: A Study of 25 Patients in a Single Center. Medical Science Monitor, 2018, 24, 961-969.	1.1	5
52	Features and Treatment of Peritoneal Metastases from Solid Pseudopapillary Neoplasms of the Pancreas. Medical Science Monitor, 2018, 24, 1449-1456.	1.1	8
53	A novel scoring system to predict ascites development post hepatectomy for BCLC stage B hepatocellular carcinoma. Translational Cancer Research, 2018, 7, 180-188.	1.0	1
54	Diagnostic and prognostic value of KRAS mutations in circulating pancreatic ductal adenocarcinoma tumor DNA. Translational Cancer Research, 2018, 7, 622-633.	1.0	7

Chun-Yi Hao

#	Article	IF	CITATIONS
55	Conversion chemotherapy with capecitabine and oxaliplatin for colorectal cancer with potentially resectable liver metastases. Journal of Cancer Research and Therapeutics, 2018, 14, 772-779.	0.9	4
56	Psoriasin promotes invasion, aggregation and survival of pancreatic cancer cells; association with disease progression. International Journal of Oncology, 2017, 50, 1491-1500.	3.3	14
57	Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma. Radiology, 2017, 283, 580-589.	7.3	36
58	Organ-preserving surgery for locally advanced duodenal gastrointestinal stromal tumor after neoadjuvant treatment. BioScience Trends, 2017, 11, 483-489.	3.4	13
59	Superior mesenteric artery margin in pancreaticoduodenectomy for pancreatic adenocarcinoma. Oncotarget, 2017, 8, 7766-7776.	1.8	9
60	LAPTM4B-35 expression was correlated with favorable post-operation survival in pancreatic cancer patients. Translational Cancer Research, 2017, 6, 709-719.	1.0	0
61	Suppression of CD26 inhibits growth and metastasis of pancreatic cancer. Tumor Biology, 2016, 37, 15677-15686.	1.8	8
62	PTK7 overexpression in colorectal tumors: Clinicopathological correlation and prognosis relevance. Oncology Reports, 2016, 36, 1829-1836.	2.6	29
63	Relationship between LAPTM4B Gene Polymorphism and Prognosis of Patients following Tumor Resection for Colorectal and Esophageal Cancers. PLoS ONE, 2016, 11, e0158715.	2.5	5
64	Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget, 2016, 7, 6639-6648.	1.8	18
65	Elevated serum CD26 level is associated with metastasis and post-operation survival in pancreatic cancer patients. Translational Cancer Research, 2016, 5, 512-519.	1.0	5
66	Fusobacterium nucleatum infection is correlated with tumor metastasis and postoperative survival of colorectal cancer patients in China. Translational Cancer Research, 2016, 5, 579-588.	1.0	12
67	IL24 and its Receptors Regulate Growth and Migration of Pancreatic Cancer Cells and Are Potential Biomarkers for IL24 Molecular Therapy. Anticancer Research, 2016, 36, 1153-63.	1.1	8
68	Expression of CD147 and matrix metalloproteinase-11 in colorectal cancer and their relationship to clinicopathological features. Journal of Translational Medicine, 2015, 13, 337.	4.4	26
69	Castleman disease of the mesentery as the great mimic: Incidental finding of one case and the literature review. BioScience Trends, 2015, 9, 198-202.	3.4	7
70	Ischemic Liver Injury After Complete Occlusion of Hepatic Artery in the Treatment of Delayed Postoperative Arterial Bleeding. Journal of Gastrointestinal Surgery, 2015, 19, 2235-2242.	1.7	7
71	Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6496-505.	7.1	313
72	Efficacy and safety of capecitabine plus oxaliplatin (XELOX) as the perioperative treatment of patients with potentially resectable liver-only metastases from colorectal cancer: A single arm, open-label, multicenter phase II trial (ML22298; NCT00997685) Journal of Clinical Oncology, 2015, 33, 777-777.	1.6	0

CHUN-YI HAO

#	Article	IF	CITATIONS
73	Expression of SATB1 Promotes the Growth and Metastasis of Colorectal Cancer. PLoS ONE, 2014, 9, e100413.	2.5	43
74	CD44-Positive Cancer Stem Cells Expressing Cellular Prion Protein Contribute to Metastatic Capacity in Colorectal Cancer. Cancer Research, 2013, 73, 2682-2694.	0.9	84
75	En Bloc Pancreaticoduodenectomy and Right Colectomy in the Treatment of Locally Advanced Colon Cancer. Diseases of the Colon and Rectum, 2013, 56, 874-880.	1.3	26
76	Expression of MMP-9 and WAVE3 in colorectal cancer and its relationship to clinicopathological features. Journal of Cancer Research and Clinical Oncology, 2012, 138, 2035-2044.	2.5	35
77	Solid Pseudopapillary Tumor of the Pancreas: Report of 8 Cases in a Single Institution and Review of the Chinese Literature. Pancreatology, 2006, 6, 291-296.	1.1	14
78	Longitudinal and timeâ€ŧoâ€event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma. CPT: Pharmacometrics and Systems Pharmacology, 0, , .	2.5	3